AB9986

Anti-Osteoprotegerin 抗体

Name: Anti-Osteoprotegerin 抗体 (ab9986) | Abcam
Brand: Abcam Limited
SKU: AB9986
Price: 76000 JPY
Availability: InStock
Rating: 3 (1 reviews)

Anti-Osteoprotegerin antibody

(1 Review)

(24 Publications)

Rabbit Polyclonal Osteoprotegerin antibody. Suitable for WB and reacts with Human samples. Cited in 24 publications. Immunogen corresponding to Recombinant Fragment Protein within Human TNFRSF11B.

別名を表示する

OCIF, OPG, TNFRSF11B, Tumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin

1 Images

Unknown

Western blot - Anti-Osteoprotegerin antibody (AB9986)

Osteoprotegerin contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted.

All lanes:

Western blot - Anti-Osteoprotegerin antibody (ab9986) at 1 µg/mL

Lane 1:

U2OS (Human osteosarcoma cell line) Whole Cell Lysate at 10 µg

Lane 2:

HEK293 (Human embryonic kidney cell line) Whole Cell Lysate at 10 µg

Secondary

All lanes:

Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution

Predicted band size: 46 kDa

Observed band size: 32 kDa,56 kDa

true

Exposure time: 150s

Key facts

宿主種

Rabbit

クローン性

Polyclonal

アイソタイプ

Unknown

軽鎖のタイプ

unknown

キャリアフリー

交差種

Human

アプリケーション

applications

免疫原

Recombinant Fragment Protein within Human TNFRSF11B. The exact immunogen used to generate this antibody is proprietary information.

O00300

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "0.1-1 µg/mL", "WB-species-notes": "<p>To detect hOPG by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 μg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hOPG is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.</p>" } } }

style

left-column

製品の詳細

This product is no longer batch tested in IHC, for an IHC validated antibody please see ab124820

style

left-column

出荷温度及び保存条件

製品の状態

Lyophilized

再構成

Reconstitute with 200µl of sterile water. Please note that if you receive this product in liquid form it has already been reconstituted as described and no further reconstitution is necessary.

精製方法

Affinity purification Immunogen

出荷温度

Blue Ice

短期保存期間

1-2 weeks

短期保存温度

+4°C

長期保存温度

-20°C

分注に関する情報

Upon delivery aliquot

style

left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

Osteoprotegerin (OPG) also known as osteoclastogenesis inhibitory factor is a glycoprotein with a mass of approximately 60 kDa. It acts as a soluble decoy receptor for receptor activator of nuclear factor kappa-Β ligand (RANKL) and is encoded by the TNFRSF11B gene. OPG is mainly expressed in osteoblasts fibroblasts and endothelial cells. Its expression can be found in diverse tissues throughout the body including the liver and lungs.

Biological function summary

OPG inhibits the differentiation and activation of osteoclasts by binding to RANKL preventing its interaction with the receptor RANK on the surface of osteoclast progenitor cells. As part of a non-classical signaling pathway OPG plays a significant role in the regulation of bone remodeling and maintenance by controlling bone resorption. This activity preserves bone density and structure by limiting excessive osteoclastic activity.

Pathways

OPG operates within the RANK/RANKL/OPG signaling axis which is important for bone metabolism. It counteracts the bone-resorption pathway driven by the RANKL-RANK interaction inhibiting osteoclastogenesis. This axis involves interactions with other proteins such as RANK RANKL and TRAIL where TRAIL’s involvement hints towards a broader immune regulation role for OPG.

OPG has a significant association with conditions such as osteoporosis and vascular calcification. In osteoporosis an imbalance in the RANKL/OPG ratio can lead to excessive bone loss due to increased osteoclast activity. In vascular calcification OPG appears to play a protective role likely linked with regulatory mechanisms involving RANKL and TRAIL. Understanding these interactions opens potential therapeutic avenues particularly in managing bone-related and cardiovascular conditions.

style

left-column

style

left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

ターゲットの情報

Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.

See full target information TNFRSF11B

style

left-column

文献 (24)

Recent publications for all applications. Explore the full list and refine your search

Quantitative imaging in medicine and surgery 14:4403-4416 PubMed39022252

2024

The mechanism of bone metabolism in a Sprague Dawley rat model of mandibular osteoradionecrosis.

Applications

Unspecified application

Species

Unspecified reactive species

Shanshan Liu,Bin Zhang,Shengnan Ma,Feiguang Wu,Xiaona Shi,Jiandong Wu,Ole T Jensen,Paolo Cariati,Jinsheng Hong,Xiaofeng Zhu

Open life sciences 18:20220663 PubMed37589010

2023

Effect of periostin on bone metabolic and autophagy factors during tooth eruption in mice.

Applications

Unspecified application

Species

Unspecified reactive species

Han Qin,Jun Cai

Cellular and molecular biology (Noisy-le-Grand, France) 69:125-131 PubMed37605579

2023

Expression of spleen macrophages in a mouse model of alveolar bone resorption periodontitis.

Applications

Unspecified application

Species

Unspecified reactive species

Yixin Xu,Yixin Wang,Yongming Li

Frontiers in bioengineering and biotechnology 11:1070117 PubMed36815882

2023

Eldecalcitol effectively prevents alveolar bone loss by partially improving Th17/Treg cell balance in diabetes-associated periodontitis.

Applications

Unspecified application

Species

Unspecified reactive species

Ruihan Gao,Weidong Zhang,Yujun Jiang,Junzhe Zhai,Jian Yu,Hongrui Liu,Minqi Li

FASEB journal : official publication of the Federation of American Societies for Experimental Biology 37:e22711 PubMed36520091

2022

Melatonin promotes the restoration of bone defects via enhancement of miR-335-5p combined with inhibition of TNFα/NF-κB signaling.

Applications

Unspecified application

Species

Unspecified reactive species

Yiyang Li,Huanshuai Guan,Run Tian,Ning Kong,Guanzhi Liu,Zhe Li,Kunzheng Wang,Pei Yang

BMC oral health 22:290 PubMed35842599

2022

Mechanical force regulates root resorption in rats through RANKL and OPG.

Applications

Unspecified application

Species

Unspecified reactive species

Jianli Zhou,Lijia Guo,Yanji Yang,Yi Liu,Chen Zhang

Frontiers in immunology 12:742358 PubMed34938284

2021

TNFRSF11B Suppresses Memory CD4+ T Cell Infiltration in the Colon Cancer Microenvironment: A Multiomics Integrative Analysis.

Applications

Unspecified application

Species

Unspecified reactive species

Jun-Rong Zhang,Ping Hou,Xiao-Jie Wang,Zong-Qi Weng,Xin-Chang Shang-Guan,Hui Wang,Fang You,Bing-Qiang Lin,Zheng-Yuan Huang,Xian-Qiang Chen

Brazilian dental journal 32:16-25 PubMed33913997

2021

RANK, RANKL, and OPG in Dentigerous Cyst, Odontogenic Keratocyst, and Ameloblastoma: A Meta-Analysis.

Applications

Unspecified application

Species

Unspecified reactive species

Igor Felipe Pereira Lima,Felipe Rodrigues de Matos,Ítalo de Macedo Bernardino,Ingrede Tatiane Serafim Santana,Walbert de Andrade Vieira,Cauane Blumenberg,Walter Luiz Siqueira,Luiz Renato Paranhos

Frontiers in pharmacology 11:609119 PubMed33574755

2021

Bunting Total Alkaloids Attenuate Walker 256-Induced Bone Pain and Osteoclastogenesis by Suppressing RANKL-Induced NF-κB and c-Fos/NFATc1 Pathways in Rats.

Applications

Unspecified application

Species

Unspecified reactive species

Linjie Ju,Peipei Hu,Ping Chen,Jiejie Wu,Zhuoqun Li,Zhixia Qiu,Jun Cheng,Fang Huang

International journal of endocrinology 2020:8821077 PubMed33488706

2020

Liraglutide Promotes Osteoblastic Differentiation in MC3T3-E1 Cells by ERK5 Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Yue Sun,Yuzhen Liang,Zhengming Li,Ning Xia

View all publications

style

left-column

style

left-column

style

right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。

保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-Osteoprotegerin 抗体

Anti-Osteoprotegerin antibody

Western blot - Anti-Osteoprotegerin antibody (AB9986)

Key facts

宿主種

クローン性

アイソタイプ

軽鎖のタイプ

キャリアフリー

交差種

アプリケーション

免疫原

代替製品

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

組合せ製品

Assay Kits

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity data

製品の詳細

出荷温度及び保存条件

製品の状態

再構成

精製方法

出荷温度

短期保存期間

短期保存温度

長期保存温度

分注に関する情報

補足情報

Biological function summary

Pathways

製品プロトコール

ターゲットの情報

文献 (24)

Abcam product promise